Profound Medical Corp. (PROF) stock
PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$7.44−0.41 (-5.22%)
Close on Nov 12, 2026Market cap $271.80MP/E –Yield –
Profound Medical r&d expenses
Research and development expenses are spending on new products and technology.
Profound Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $20.99M, up 0.1% year over year. For fiscal 2025 it was $20.60M, up 21.4% from the year before. The highest annual figure on record is $20.60M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.60M | +21.4% |
| FY2024 | Dec 31, 2024 | $16.97M | +17.6% |
| FY2023 | Dec 31, 2023 | $14.42M | -1.8% |
| FY2022 | Dec 31, 2022 | $14.69M | -3.8% |
| FY2021 | Dec 31, 2021 | $15.28M | +54.1% |
| FY2020 | Dec 31, 2020 | $9.91M | +5.5% |
| FY2019 | Dec 31, 2019 | $9.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.81M | +7.2% |
| Q2 FY2026 | Jun 30, 2026 | $5.65M | -7.3% |
| Q1 FY2026 | Mar 31, 2026 | $5.26M | +9.4% |
| Q4 FY2025 | Dec 31, 2025 | $4.27M | -8.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.42M | +30.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.10M | +45.0% |
| Q1 FY2025 | Mar 31, 2025 | $4.81M | +21.9% |
| Q4 FY2024 | Dec 31, 2024 | $4.65M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.17M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.21M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.95M | – |
See a number that looks wrong?